



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/202, 31/203, 31/352, 31/192, 31/381, 31/196, 31/655, 31/382, 31/235, A61P 19/02, 19/08	A1	(11) International Publication Number: WO 00/30635 (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/CA99/01106 (22) International Filing Date: 19 November 1999 (19.11.99) (30) Priority Data: 2,254,429 19 November 1998 (19.11.98) CA (71) Applicant (for all designated States except US): THE UNIVERSITY OF WESTERN ONTARIO [CA/CA]; Office of Industry Liaison, Stevenson-Lawson Building, Room 319, London, Ontario N6A 5B8 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): UNDERHILL, Tully, Michael [CA/CA]; The University of Western Ontario, Division of Oral Biology, School of Dentistry, London, Ontario N6A 5C1 (CA). WESTON, Andrea, Dawn [CA/CA]; The University of Western Ontario, The Faculty of Medicine & Dentistry, Department of Physiology, London, Ontario N6A 5C1 (CA). (74) Agent: RAE, Patricia, A.; Sim & McBurney, 6th Floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING CHONDROGENESIS (57) Abstract The invention provides compositions comprising a RAR antagonist for promoting chondrogenesis and to methods employing such compositions for treating cartilage and associated bone abnormalities resulting from injury or disease and for <i>ex vivo</i> tissue engineering.		